A successful start-up has the capacity to translate vision into reality
Following our investment from IP Group Simon Graindorge, Experienced Life Science Investor, shares why Oxehealth caught his eye. In this fifth and final blog, Simon discusses our attributes and what start-ups need to be successful.
So far Simon has covered the beating heart of a start-up, the team, the importance of predicting the market and then adapting a strong strategy. So what's next?
Vital sign 5. Oxygen saturation Execution plan and funding
Just like spending energy to pump blood around your body is all a bit pointless if your blood isn't full of oxygen, you need a credible and feasible plan of how you are going to execute your strategy and deliver that big vision. The plan should look to reduce the risks and focus on actually delivering that end game. We know from experience how long and hard the road is for these early-stage technologies.
IP Group provided initial capital and support which enabled Oxehealth to progress technically, validate markets and identify and secure an expert management team. It's pleasing to note that all of this work positioned the company optimally to successfully secure £2m fundraising in April which, alongside continued investment from IP Group, saw a new shareholder come on board well-known technology investor, Ora.
We remain excited about the opportunities for Oxehealth and will continue to lend our support as it strives to develop a business that will produce meaningful returns for all of its stakeholders.
Missed the first four instalments? Don't worry, read Simon's thoughts on how to become a successful start-up here:
If you have any questions about the science behind Oxecam? contact the team here here.